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 Background: The use of oncolytic adenoviruses as cancer gene 
therapy is limited by their uneven penetration and distribu-
tion in tumors. We investigated whether the expression of 
the cell matrix – degradative protein relaxin by adenovirus 
could improve adenovirus distribution and penetration in 
tumors.  Methods: We generated relaxin-expressing, replica-
tion-incompetent (dl-lacZ-RLX) and -competent (Ad- Δ E1B-
RLX) adenoviruses by inserting a relaxin gene into the E3 
adenoviral region. Controls were parental adenoviruses (dl-
lacZ and Ad- Δ E1B) and phosphate-buffered saline (PBS) 
(vehicle). Replication-incompetent viruses, which do not lyse 
cells, were used to assess transduction effi ciency. Viral spread 
in tumor spheroids, made by dissecting tumor tissue into 
homogeneous fragments, was assessed by reporter gene (i.e., 
lacZ) expression. Tumor growth inhibition was assessed by 
injecting adenoviruses into xenograft tumors in athymic mice 
(n = 8 or 9). Overall survival was assessed by the Kaplan –
 Meier method. Extracellular matrix was examined with 
Masson’s trichrome staining. Therapeutic effi cacy was evalu-
ated by assessing spontaneous pulmonary metastasis in the 
B16BL6 melanoma mouse model and growth inhibition of 
orthotopically implanted hepatoma (n = 4 – 6). All statistical 
tests were two-sided.  Results: In tumor spheroids and estab-
lished solid tumors in vivo, transduction with dl-lacZ-RLX, 
compared with parental virus or vehicle, elicited higher trans-
duction effi ciency and viral spread throughout the tumor 
mass. Infection with Ad- Δ E1B-RLX, compared with parental 
virus, elicited greater viral persistence and spread, leading to 
increased survival (e.g., 100%, 95% confi dence interval [CI] = 
63.1% to 100%, for C33A tumor-bearing mice treated with 
Ad- Δ E1B-RLX, and 50%, 95% CI = 15.7% to 84.3%, for 
C33A tumor-bearing mice treated with Ad- Δ E1B). Infection 
with Ad- Δ E1B-RLX substantially decreased the collagen con-
tent of tumor tissue but not of adjacent normal tissue, com-
pared with noninfected tissues. Intratumoral injection of 
Ad- Δ E1B-RLX inhibited the formation of lung metastases in 
mice (PBS = 268 mg of metastatic tumor per mouse and 
Ad- Δ E1B-RLX = 10 mg; difference = 258 mg, 95% CI = 94 to 
426;  P = .003, Mann – Whitney test). Systemic treatment with 
Ad- Δ E1B-RLX completely inhibited the growth of Hep1 
hepatocellular carcinomas (PBS = 20.2 mg of tumor per 
mouse and Ad- Δ E1B-RLX = 0 mg; difference = 20.2 mg, 95% 
CI = 3.7 to 36.7;  P = .004, Mann – Whitney test).  Conclusion: 
Extracellular matrix degradation by relaxin expressed by 
adenoviruses increased viral distribution and tumor penetra-
tion, inhibited tumor growth and metastasis, and increased 
survival of mice. [J Natl Cancer Inst 2006;98: 1482 – 93 ] 
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 Relaxin Expression From Tumor-Targeting Adenoviruses 
and Its Intratumoral Spread, Apoptosis Induction, 
and Effi cacy 
 Joo-Hang  Kim ,  Young-Sook  Lee ,  Hoguen  Kim ,  Jing-Hua  Huang ,  A-Rum  Yoon , 
 Chae-Ok  Yun 
 Although the selective replication and spread of oncolytic ad-
enoviruses within cancer cells and tissues has had some success 
as an anticancer treatment, its promise has been limited because 
of the uneven penetration and distribution of these viruses in 
 tumor tissues. To date, ONYX-015, an oncolytic adenovirus in 
which the E1B 55-kDa gene has been deleted, has been adminis-
tered to more than 300 cancer patients with various tumor types 
 ( 1 , 2 ) but has had only limited success (i.e., local tumor regres-
sion rates of 0% – 14%). Sauthoff et al.  ( 3 ) demonstrated that high 
levels of adenoviruses persisted in xenograft tumors for at least 8 
weeks after intratumoral injection of wild-type adenoviruses, but 
the viral distribution pattern in the tumor tissue was uneven and 
patchy. Harrison et al.  ( 4 ) detected a high level of viruses in 
 persistent viable tumors up to 100 days after the initial viral in-
jection. Thus, despite long-term viral persistence in tumors, the 
limited spread of virus to cells throughout the tumor could 
explain the low response rates observed. 
 Connective tissue and the extracellular matrix appear to play 
a role in inhibiting viral spread in tumors. Kuriyama et al.  ( 5 ) 
demonstrated that treatment of human U87, U251, or SF767 glio-
blastoma multiforme – derived brain tumor xenografts with col-
lagenase, dispase, or trypsin, before the intratumoral injection of 
adenovirus enhanced virus-mediated gene transduction, and 
Maillard et al.  ( 6 ) reported that elastase pretreatment before de-
livery of adenoviral vectors into rabbit iliac arteries increased 
viral transduction effi ciency. 
 Relaxin is a peptide hormone that is structurally related to 
insulin and insulin-like growth factors  ( 7 ) . Treatment of human 
lung fi broblasts and bleomycin-induced mouse lung fi brosis 
(i.e., the common end stage of many pneumopathies) tumors 
with relaxin decreases the synthesis and secretion of interstitial 
collagens and increases the expression of matrix metallopro-
teinase and procollagenase  ( 8 ) . Relaxin is a potent inhibitor of 
collagen expression when collagen is overexpressed, but it does 
not markedly alter basal levels of collagen expression, in con-
trast to other collagen-modulatory cytokines, such as interferon 
gamma  ( 9 ) . To further explore the barrier role of the  extracellular 
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matrix and connective tissue in inhibiting viral spread and pen-
etration within tumor masses, we determined whether the ex-
pression of relaxin by adenoviruses increases their spread in 
tumor tissues. 
 M ATERIALS  AND M ETHODS 
 Cell Lines and Cell Culture 
 The human embryonic kidney cell line 293 that expresses the 
adenoviral E1 region, the brain cancer cell lines U343 and 
U87MG, the cervical cancer cell line C33A, the liver cancer 
cell line Hep3B, and the non – small lung cancer cell line A549 
were purchased from the American Type Culture Collection 
(ATCC, Manassas, VA). Murine B16BL6 melanoma cells (a 
metastatic variant of B16 melanoma cells) were obtained from 
Dr Y. S. Park (Yonsei University, Wonju, South Korea). All cell 
lines were cultured in Dulbecco’s modifi ed Eagle medium 
(DMEM; Gibco BRL, Grand Island, NY) supplemented with 
10% fetal bovine serum (Gibco BRL), 2 mM  l -glutamine, peni-
cillin (100 IU/mL), and streptomycin (50  μ g/mL), except for 
Hep3B cells, which were cultured in modifi ed Eagle medium 
(MEM; Gibco BRL), and B16BL6 cells, which were cultured in 
MEM supplemented with 5% fetal bovine serum, MEM vitamin 
solution (1 mM; Gibco BRL, product 11120-052), 100 mM so-
dium pyruvate, 10 mM of MEM nonessential amino acids solu-
tion (10 mM; Gibco BRL, product 11140-050), penicillin (500 
IU/mL), and streptomycin (50  μ g/mL). All cell lines were main-
tained at 37 °C in a humidifi ed atmosphere at 5% CO 2 and 95% 
air.  Escherichia coli was propagated in Luria Bertani medium 
at 37 °C. 
 Generation of Relaxin-Expressing Adenoviruses 
 To generate adenoviruses that express relaxin at the E3 region, 
we fi rst excised the relaxin gene from the vector pDNR-LIB-RLX 
(ATCC) with the endonucleases  Sal I and  Hin dIII and subcloned 
into the vector pCA14 (Microbix, Ontario, Canada) to generate 
pCA14-RLX. CMV-relaxin-polA expression cassette was then 
excised from pCA14-RLX and cloned into the adenovirus E3 
shuttle vector pSP72-E3 ( 10) that had been predigested with the 
endonuclease  Bam HI to generate pSP72-E3/CMV-RLX. The 
newly constructed pSP72-E3/CMV-RLX shuttle vector was then 
linearized with  Pvu I digestion. The replication-incompetent ade-
noviral vector pdl-lacZ that expresses lacZ (i.e.,  β -galactosidase) 
at E1 region of adenovirus and E1B 19-kDa – and E1B 55-kDa –
 deleted replication-competent adenoviral vector pAd- Δ ElB were 
linearized with  Spe I digestion. The linearized pSP72-E3/CMV-
RLX shuttle vector was then cotransformed into  E. coli BJ5183 
with the  Spe I-digested pdl-lacZ or pAd- Δ ElB for homologous 
 recombination  ( 11 ) to generate pdl-lacZ-RLX and pAd- Δ E1B-
 RLX adenoviral vector, respectively ( Fig. 1 , A). E1-deleted 
replication-incompetent adenovirus (dl-lacZ) and E1B 19-kDa – 
and E1B 55-kDa – deleted replication-competent adenovirus 
(Ad- Δ ElB) were also prepared as previously described  ( 12 ) . All 
viruses were propagated in 293 cells, and the purifi cation, titra-
tion, and quality analysis of all adenoviruses used were performed 
as previously described  ( 13 ) . The number of viral particles was 
calculated from measurements of optical density at 260 nm, 
where 1 absorbency unit is equivalent to 10 12 viral particles 
per milliliter, and infectious titers (plaque-forming units per mil-
liliter) were determined by limiting dilution assay on 293 cells; 
the plaque-forming unit was calculated from infectious titers as 
follows: T = 10 1+ d ( S – 0.5) , where  d and  S were the log 10 of the dilu-
tion and the sum of ratios, respectively. The viral particle/plaque-
forming unit ratios for dl-lacZ, dl-lacZ-RLX, Ad- Δ ElB, and 
Ad- Δ ElB-RLX were 57 : 1, 70 : 1, 22 : 1, and 43 : 1, respectively. 
 Enzyme-Linked Immunosorbent Assay for Relaxin 
Expression 
 We infected 5 × 10 5 U343 or C33A cells with dl-lacZ, dl-lacZ-
RLX, Ad- Δ E1B, or Ad- Δ E1B-RLX at various multiplicities of 
infection (MOIs) in 25-T culture fl asks. Forty-eight hours later, 
the supernatant was collected by centrifugation at 15 000 g for 
10 minutes at 4 °C, and the level of relaxin protein was assessed 
by enzyme-linked immunosorbent assay (Endogen, Woburn, 
MA). Serial dilutions of a purifi ed recombinant human relaxin 
preparation with a known concentration were used to generate a 
standard curve. 
 Animal Studies 
 Male athymic nu/nu and C57BL/6 mice, weighing approxi-
mately 20 g at 6 – 8 weeks of age, were obtained from Charles 
River Japan Inc (Yokohama, Japan). All mice were maintained in 
a laminar airfl ow cabinet under specifi c pathogen-free condi-
tions. All facilities are approved by the Association of Assess-
ment and Accreditation of Laboratory Animal Care, and 
all animal experiments were conducted under the institutional 
guidelines established for the Animal Core Facility at Yonsei 
University College of Medicine. 
 Preparation of Tumor Spheroids and the 
Spreading and Penetration of Relaxin-Expressing 
Replication-Incompetent Adenovirus dl-lacZ-RLX 
in Spheroids 
 Xenografts of U343, U87MG, C33A, or A549 cells were es-
tablished by subcutaneously injecting 1 × 10 7 cells into the abdo-
men of 6- to 8-week-old male nude mice (Charles River Japan 
Inc). When a tumor reached a volume of 150 – 200 mm 3 (3 – 4 
weeks), tumor tissue was surgically excised, blood and necrotic 
tissue were removed from the tissue, and tumor fragments 
1 – 2 mm in diameter were dissected with sterile 21-gauge  needles. 
These explants (i.e., 30 – 50 explants) were plated individually 
on 1.45% agarose-coated 48-well plates and cultured in DMEM 
supplemented with 10% fetal bovine serum. Cultures received 
fresh medium once every 2 weeks. For our experiments, we used 
only those explants that became spherical (i.e., spheroids) and 
that were approximately 2 mm in diameter. 
 For transduction of tumor spheroids, 100  μ L of culture me-
dium was removed from each tumor spheroid culture dish by as-
piration, and 50  μ L of adenovirus dl-lacZ or dl-lacZ-RLX in 
culture medium (i.e., 1 × 10 8 , 1 × 10 9 , or 1 × 10 10 viral particles) 
was added. Three days later,  β -galactosidase expression in each 
tumor spheroid was assessed by use of 5-bromo-4-chloro-3-
 indolyl- β - d -galactopyranoside (Life Technologies, Rockville, 
MD), as described previously  ( 14 ) . Each experiment was carried 
out three to four times with three replicates in each group, and the 
results were similar in all experiments. Data from a representa-
tive experiment are shown. 
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on June 19, 2014
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
1484 ARTICLES Journal of the National Cancer Institute, Vol. 98, No. 20, October 18, 2006
 Spreading and Penetration of dl-lacZ-RLX In Vivo 
 To determine the extent of viral spread and tumor penetration, 
subcutaneous xenografts of U343, U87MG, C33A, Hep3B, and 
A549 cells were established by injecting 1 × 10 7 cells into the ab-
do men of 6- to 8-week-old male nude mice (123 mice total). When 
tumors reached a volume of 100 – 200 mm 3 , mice were  randomly 
assigned to receive either dl-lacZ or dl-lacZ-RLX adenovirus 
from 5 × 10 9 to 5 × 10 10 viral particles per 50  μ L that was intratu-
morally injected into the tumors three times, every other day. 
Three days after the last injection of virus, animals were killed by 
decapitation, and tumors were excised to determine viral distribu-
tion by assessing  β -galactosidase expression with 5-bromo-4-
chloro-3-indolyl- β - d -galactopyranoside  ( 15 ) . For better quantitation 
of  β -galactosidase gene activity in tumor tissue, entire tumors 
were homogenized in lysis buffer (60 mM Na 2 HPO 4 , 40 mM 
NaH 2 PO 4 , 10 mM KCl, 1 mM MgSO 4 , and 0.1% Nonidet P-40, 
at pH 7.0) with a homogenizer (ART Labo rtecnik, Müllheim, 
Germany). The supernatant was collected by centrifugation at 
15 000 g for 10 minutes at 4 °C. The  β -galactosidase activity was 
measured in the supernatant by use of an enhanced  β - galactosidase 
assay kit (Gene Therapy Systems Inc, San Diego, CA) and then 
normalized to the total protein content of the extract. The protein 
content of the extracts was measured with a BCA protein assay kit 
(Pierce Biotechnology, Rockford, IL). Transduction effi ciency 
was expressed as total cellular  β -galactosidase activity per total 
protein content of each tumor. 
 Plaque Development Assay 
 Monolayers of Hep3B cells were infected with adenoviruses at 
an MOI of 1 × 10  − 4 in six-well plates. After a 4-hour incubation at 
37 °C, the infected cells were overlayed with 4 mL of 0.7% Ultra-
Pure agarose (Invitrogen, Carlsbad, CA) in DMEM with 5% fetal 
bovine serum. After 4 – 16 days of incubation, the agarose overlay 
was removed after soaking with 10% trichoroacetic acid for 30 min-
utes, and the remaining cells were stained with 0.5% crystal violet 
in 50% methanol. The number of plaques on any given day was 
plotted as the percentage of plaques on the fi nal day of the assay. 
 Terminal Deoxynucleotidyltransferase-Mediated 
Deoxyuridine Triphosphate Nick End Labeling Assay 
 Apoptosis was examined by use of the terminal deoxynucleo-
tidyltransferase-mediated deoxyuridine triphosphate nick end 
labeling (TUNEL) assay. U343, U87MG, C33A, Hep3B, and 
A549 cells were fi rst plated onto chamber slides at a density of 
5 × 10 4 cells per chamber. Twenty-four hours later, cells were 
infected with dl-lacZ or dl-lacZ-RLX adenovirus at an MOI of 
5 – 10 or with Ad- Δ E1B or Ad- Δ E1B-RLX adenovirus at an MOI 
of 0.1 – 5 for 48 hours. Apoptotic cells were identifi ed by detect-
ing cleaved deoxyribonucleic acid by use of the in situ ApopTag 
kit (Chemicon International, Temecula, CA) according to the 
manufacturer’s instructions. The apoptotic cells were visually 
identifi ed in 10 selected fi elds and photographed at a magnifi ca-
tion of ×400. More than 2000 cells were counted to calculate the 
percentage of TUNEL-positive cells (apoptotic cell ratio). To 
 detect apoptotic cells in vivo, formalin-fi xed tissue sections were 
prepared and processed as described previously  ( 10 ). Briefl y, 
 tumor sections (8  μ m thick) were treated with proteinase K 
(20  μ g/mL) for 15 minutes, and then endogenous peroxidase was 
blocked by treating sections with 3% hydrogen peroxide in phos-
phate-buffered saline (PBS) for 10 minutes. Sections were then 
incubated with terminal deoxynucleotidyltransferase buffer for 1 
hour at 37 °C and were treated with an anti-digoxignenin anti-
body conjugate for 30 minutes. Standard avidin – biotin immuno-
histochemical techniques were used to cleave deoxyribonucleic 
acid according to the manufacturer’s recommendations (Chemi-
con International). Diaminobenzidine was used as a chromogen, 
and 0.5% methyl green was used as counterstain. 
 Flow Cytometry Analysis 
 Development of apoptosis and cell nuclear damage were de-
termined by dual staining with annexin-V – fl uorescein isothio-
cyanate and propidium iodide and analyzed by fl ow cytometry. 
Cells were infected with dl-lacZ or dl-lacZ-RLX adenovirus at an 
MOI of 20 – 50 or with Ad- Δ E1B or Ad- Δ E1B-RLX adenovirus 
at an MOI of 0.5 – 20. As a positive control for the induction of 
apoptosis, cells were treated with 1  μ M camptothecin. After 
2 days of infection or treatment with camptothecin, cells were 
processed according to manufacturer’s instruction in the ApoAlert 
Annexin V – FITC apoptosis kit (Clontech, Palo Alto, CA). Apop-
tosis and nuclear cell damage were quantifi ed on a fl uorescence-
activated cell sorter (FACS) (Becton Dickinson, Sunnyvale, CA), 
and data from 10 000 events were collected for further analysis. 
 Antitumor Effects of Relaxin-Expressing Adenovirus in 
Human Xenograft Models 
 Xenograft tumors were implanted in the abdomens of 5- to 6-
week-old male nude mice by subcutaneous injection of 1 × 10 7 
U343, U87MG, C33A, Hep3B, or A549 cancer cells in 100  μ L of 
Hanks’ balanced salt solution (Gibco BRL). When tumors 
reached a volume of 60 – 80 mm 3 , mice were randomly assigned 
to one of three groups to receive PBS, Ad- Δ E1B, or Ad- Δ E1B-
RLX (eight or nine mice per group). The fi rst day of treatment 
was designated as day 1. Adenovirus or PBS was administered 
intratumorally (for C33A tumors, 1 × 10 10 viral particles per tu-
mor in 50  μ L of PBS, and for U343, U87MG, Hep3B, or A549 
tumors, 5 × 10 10 viral particles per tumor in 50  μ L of PBS) on 
days 1, 3, and 5. Tumor growth delay was assessed by taking 
measurements every 2 or 3 days. Tumor volume was calculated 
by the following formula: volume = 0.523 LW 2 , where  L is length 
and  W is width. Tumor responses to each treatment were  compared 
by use of the Mann – Whitney test. The percentage of surviving 
mice was determined by monitoring the death of mice (for 
U87MG tumors) or tumor growth – related events (tumor size of 
>1000 mm 3 for A549 xenograft tumors or tumor size of >2000 mm 3 
for U343, C33A, and Hep3B xenograft tumors) over a period of 
80 days. Various endpoints were used for each tumor type  because 
growth characteristics of each tumor model were different. 
 Evaluation of Tumor Xenograft by Histology and 
Immunohistochemistry 
 Tumor tissue was fi xed in 10% formalin and embedded in paraf-
fi n (Wax-it, Vancouver, Canada), and 3- μ m sections were cut. Rep-
resentative sections were stained with hematoxylin – eosin or with 
Masson’s trichrome and then examined by light microscopy. We 
used reagents supplied by DAKO ARK (Dako, Carpinteria, CA) to 
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detect adenovirus antigens, as described previously  ( 16 ) . The same 
paraffi n slides were also used to identify apoptotic cells in tumors 
according to the instructions in the ApopTag kit for detecting 
cleaved deoxyribonucleic acids in situ with the TUNEL method. 
 Murine B16BL6 Spontaneous Lung Metastasis Model 
 A spontaneous metastasis model was used to examine the effect 
of increased relaxin gene expression on tumor metastasis. Briefl y, 
2 × 10 5 B16BL6 cells per mouse were administered subcutaneously 
into the right hind footpad of a 6-week-old male C57BL/6 mouse 
(Charles River Korea, Seoul, Korea). When the tumor reached a 
volume of approximately 200 mm 3 , mice were randomly assigned 
to one of three groups to receive PBS, Ad- Δ E1B, or Ad- Δ E1B-
RLX (fi ve mice per group). The fi rst day of treatment was  designated 
as day 1, and then 5 × 10 10 viral particles per tumor in 50  μ L of 
PBS, mixed with Lipofectamin and Plus solution (Gibco BRL) at a 
2 (2  μ L) : 6 (6  μ L) ratio or PBS was injected directly into the tumor 
on days 1, 3, and 5. On day 7, primary tumors were surgically re-
moved by amputating the right hind leg below the knee under mild 
anesthesia. On day 25 after primary tumor removal, the weight of 
metastatic tumor lesions in the lungs of the mice was assessed. 
 Orthotopic Hepatocellular Carcinoma Model in 
Athymic Mice 
 To determine the effects of systemic injection of relaxin-
 expressing, replication-competent adenovirus Ad- Δ E1B-RLX on 
hepatic tumor growth, 1 × 10 5 Hep1 human hepatoma cells in 
50  μ L of Hanks’ balanced salt solution were injected directly into 
the left lobe of the liver of athymic nude mice. Seven days after 
tumor cell implantation, mice were randomly assigned to receive 
systemic treatment with PBS (5 mice) or with 2 × 10 10 Ad- Δ E1B 
(four mice) or Ad- Δ E1B-RLX (six mice) viral particles in 100  μ L 
of PBS three times every other day by tail-vein injection. At 42 
days after the tumor challenge, mice were killed by decapitation, 
and livers were excised. To determine the tumor burden of the 
excised livers, tumors were then carefully removed from the liver 
and weighed for comparison. 
 Toxicology Studies 
 Because human adenoviruses replicate only in human cells, 
toxicology studies with adenoviruses are hampered by the avail-
ability of animal models; thus, we assessed toxicity in a nonper-
missive host, 8-week-old male C58BL/6 mice. For blood analysis, 
at 3 days after intravenous (tail vein) or intratumoral administra-
tion at a dose of 2 × 10 10 dl-lacZ, dl-lacZ-RLX, Ad- Δ ElB, or 
Ad- Δ ElB-RLX adenoviral particles, blood samples were obtained 
by cardiac puncture and assayed for the aspartate aminotransfer-
ase (AST), alanine aminotransferase (ALT), and serum levels of 
T-bilirubin to assess liver function. In addition, liver tissues were 
fi xed in 10% neutral buffered formalin for 24 hours, and 5- μ m 
tissue sections were cut and stained with hematoxylin and eosin. 
Examination for tissue toxicity or damage was carried out by an 
experienced mouse pathologist who was blinded to this study. 
 Statistical Analysis 
 Data were expressed as the mean with its 95% confi dence inter-
val (CI). Statistical comparisons were made with Stat View soft-
ware (Abacus Concepts, Inc, Berkeley, CA) and the Mann – Whitney 
test (nonparametric rank sum test).  P values of less than .05 were 
considered statistically signifi cant. All statistical tests were two-
sided. Survival was assessed with the Kaplan – Meier method, and 
results were compared with a log-rank test (SPSS software, version 
12.0, SPSS Inc, Chicago, IL). Differences in survival were consid-
ered statistically signifi cant when  P values were less than .05. 
 R ESULTS 
 Transduction Effi ciency and Viral Spread of 
Relaxin-Expressing Adenovirus 
 We fi rst examined the expression of relaxin in cultured C33A 
and U343 cells after their infection with adenovirus dl-lacZ-RLX 
or Ad- Δ E1B-RLX. Infection with Ad- Δ E1B-RLX induced higher 
levels of relaxin expression than transduction with dl-lacZ-RLX 
at all MOIs examined ( Fig. 1 , B). 
 Tumor tissue spheroids were then used to evaluate the trans-
duction effi ciency and tissue penetration of relaxin-expressing 
adenoviruses. Tumor tissue spheroids provide a useful three-
 dimensional model resembling tumor tissue for assessing viral 
spread and a convenient means of maintaining primary tumor 
cells in vitro. Spheroids transduced with dl-lacZ-RLX expressed 
 β -galactosidase more strongly on their peripheral surface than 
spheroids transduced with dl-lacZ ( Fig. 1 , C and Supplementary 
 Fig. 1 , A [available at:  http://jncicancerspectrum.oxfordjournals.
org/jnci/content/vol98/issue20 ]). Cross sectioning of spheroids 
transduced with dl-lacZ demonstrated that expression of  β -galac-
tosidase was limited to a few outer layers of cells. Increasing the 
adenoviral concentration up to 1 × 10 10 viral particles per spher-
oid or analyzing gene transfer at later time points did not enhance 
the transduction of tumor cells beyond the rim of the spheroids 
(data not shown). In contrast,  β -galactosidase expression in 
spheroids transduced with dl-lacZ-RLX was observed through-
out the entire spheroid. Thus, relaxin-expressing adenovirus dl-
lacZ-RLX was transduced and spread to the core of the spheroid 
more effi ciently than the control vector dl-lacZ. 
 To determine whether the enhanced transduction effi ciency 
and viral spread of dl-lacZ-RLX observed in tumor spheroids 
would lead to an increase in lacZ gene delivery to tumor mass in 
vivo, we used xenograft tumors in mice. In all xenograft models 
examined, only a few  β -galactopyranoside – positive cells were 
observed in dl-lacZ – transduced tumors, but cells throughout dl-
lacZ-RLX – transduced tumors strongly expressed  β -galactosidase 
( Fig. 1 , D and Supplementary  Fig. 1 , B [available at:  http://jnci
cancerspectrum.oxfordjournals.org/jnci/content/vol98/issue20 ]). 
In particular, intense  β -galactosidase expression was observed 
throughout the U87MG and C33A tumor xenografts transduced 
with dl-lacZ-RLX, indicating extensive viral spread and penetra-
tion in these xenograft models. 
 To further evaluate  β -galactosidase expression in vivo, U343 
and A549 xenograft tumors were intratumorally injected one, 
three, and fi ve times with adenovirus dl-lacZ or dl-lacZ-RLX, 
and  β -galactosidase activity was assessed. Tumors transduced 
with adenovirus dl-lacZ-RLX contained higher levels of  β -
 galactosidase activity than tumors infected with the control virus 
dl-lacZ, in both U343 and A549 xenograft models ( Fig. 1 , E). We 
also observed higher gene transfer effi ciency in tumors injected 
with adenovirus fi ve times than in tumors injected one or three 
times. Thus, relaxin expression appeared to enhance transgene 
expression and viral spread in solid tumors in vitro and in vivo. 
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 Cytopathic Effect and Plaque Formation of 
Relaxin-Expressing Adenovirus 
 To achieve a clinically signifi cant therapeutic outcome, replicat-
ing adenoviral vectors must be able to be distributed effi ciently 
throughout the tumor mass and to overcome the barrier imposed by 
the extracellular matrix. In an attempt to overcome limited tumor 
mass penetration by oncolytic adenovirus, we generated an E1B-
deleted oncolytic adenovirus (termed Ad- Δ E1B-RLX) that ex-
presses relaxin. We fi rst examined Ad- Δ E1B-RLX in an in vitro 
cytopathic effect assay to determine the effect of relaxin expression 
on de novo adenoviral replication. Adenovirus Ad- Δ E1B-RLX elic-
ited a greater cytopathic effect than Ad- Δ E1B, indicating that re-
laxin expression does not inhibit viral replication (data not shown). 
 Fig. 1.  Characterization of relaxin-expressing adenoviruses.  A ) Schematic 
representations of the adenoviral vectors used in this study. All indicated 
adenoviral vectors were derived from full-length adenovirus genomes cloned and 
manipulated in  Escherichia coli as bacterial plasmids. Replication-incompetent 
adenovirus that does not express relaxin, dl-lacZ, has the whole E1 region deleted 
and expresses the reporter gene lacZ ( β -galactosidase protein) under the control 
of the constitutive cytomegalovirus (CMV) promoter inserted into the E1 region. 
Replication-competent adenovirus that does not express relaxin, Ad- Δ E1B, 
contains a normal E1A gene but lacks E1B 19-kDa and E1B 55-kDa genes. The 
replication-incompetent relaxin-expressing adenovirus dl-lacZ-RLX and the 
replication-competent relaxin-expressing adenovirus Ad- Δ E1B-RLX carry a 
relaxin gene driven by the CMV promoter that was inserted into the E3 region. 
 Δ E1 and  Δ E3 denote the deletion of E1 and E3 genes, respectively. ITR = inverted 
terminal repeat;  Ψ = packaging signal; pA = polyA sequence; IX = protein IX; 
and RLX = relaxin.  B ) Quantitative enzyme-linked immunosorbent assay results 
showing relaxin expression mediated by adenoviruses dl-lacZ-RLX and Ad-
 Δ E1B-RLX at multiplicities of infection (MOIs) between 0 and 500. Relaxin 
concentration was measured in the culture supernatant 48 hours after adenoviral 
infection with conventional enzyme-linked immunosorbent assay kits. Data are 
representative of three independent experiments with each point performed in 
quadruplicate.  Error bars indicate 95% confi dence intervals for quadruplicate 
data points.  C ) Transduction effi ciency and viral spread of relaxin-expressing 
adenovirus in tumor spheroids. We prepared tumor spheroids from the indicated 
xenograft tumors in mice. Spheroids were transduced with adenoviruses dl-lacZ, 
which did not express relaxin ( columns 1 ), or dl-lacZ-RLX, which expressed 
relaxin ( columns 2 ), at 1 × 10 8 , 1 × 10 9 , and 1 × 10 10 viral particles per 50  μ L. 
Three days after infection, spheroids were processed to visualize  β -galactosidase 
expression ( blue ) and then sectioned. Viral penetration and transduction effi ciency 
in the central areas of the spheroids were then assessed by light microscopy. In each 
panel,  columns to the left show whole spheroids (stereoscopic light microscope; 
original magnifi cation = ×38) and columns to the right show sections through 
the spheroid midpoint (original magnifi cation = ×40).  Scale bars are 400  μ m. 
 D ) Transduction effi ciency and viral spread of relaxin-expressing adenovirus in 
U343, U87MG, C33A, Hep3B, and A549 xenografts. We established xenografts 
in nude mice and then injected them intratumorally with dl-lacZ or dl-lacZ-RLX 
adenovirus (at 5 × 10 9 to 5 × 10 10 viral particles per 50  μ L) three times every other 
day. Three days after the last injection of adenovirus, tumors were harvested and 
processed to visualize  β -galactosidase expression ( blue ).  Scale bars are 400  μ m 
at ×40 and 100  μ m at ×200 magnifi cations (Original magnifi cations = ×40 and 
×200, respectively).  E ) Quantitation of the  β -galactosidase expression in tumor 
tissue treated one, three, or fi ve times with adenoviruses at 5 × 10 9 virus particles 
(v.p.) or at 1 × 10 10 v.p. that do not (dl-lacZ) or do (dl-lacZ-RLX) express relaxin. 
The transduction effi ciency was expressed as total cellular  β -galactosidase 
activity (in milliunits) per total protein content (in milligrams). Data are the 
means and 95% confi dence intervals of three independent experiments, with each 
point performed in triplicate. 
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 To visualize the effect of relaxin expression on the cytopathic 
ability and viral spread into surrounding cells, we used a plaque-
forming assay ( Fig. 2 ). Adenovirus Ad- Δ E1B, which does not 
express relaxin, generated plaques 16 days after infection, 
whereas the relaxin-expressing adenovirus Ad- Δ E1B-RLX gen-
erated plaques only 4 days after infection, demonstrating that the 
expression of relaxin is associated with the induction of early 
viral release and accelerated cell-to-cell spread of viruses. 
 Relaxin and Apoptosis 
 We used a terminal TUNEL assay to determine whether the 
increased cell killing of a relaxin-expressing adenovirus was me-
diated by the induction of apoptosis. Ad- Δ E1B-RLX induced a 
statistically signifi cantly higher percentage of all cells examined 
to undergo apoptosis than Ad- Δ E1B ( P = .025 for U343,  P = .012 
for U87MG,  P = .036 for C33A,  P = .028 for Hep3B, and  P = 
.021 for A549) ( Fig. 3 ). More specifi cally, there were 69.7% 
(95% CI = 65.0 to 74.4), 77.0% (95% CI = 61.2 to 92.8), 79.8% 
(95% CI = 61.8 to 97.8), 69.7% (95% CI = 56.0 to 83.4), and 
75.2% (95% CI = 74.1 to 76.3) of TUNEL-positive cells among 
Ad- Δ E1B-RLX – treated U343, U87MG, C33A, Hep3B, and 
A549 cells, respectively, whereas there were only 32.5% (95% 
CI = 21.5 to 43.5), 16.5% (95% CI = 11.9 to 21.1), 45.2% (95% 
CI = 38.5 to 51.9), 38.5% (95% CI = 36.2 to 40.8), and 34.8% 
(95% CI = 24.9 to 44.7), respectively, of TUNEL-positive, 
Ad- Δ E1B – treated cells. 
 The induction of apoptosis by relaxin-expressing adenovi-
ruses was also evaluated with fl ow cytometry in several cell lines 
( Table 1 ). Healthy cells are negative for annexin-V and propid-
ium iodide, whereas early apoptotic cells are positive for 
annexin-V and negative for propidium iodide. When U343 cells 
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 Fig. 2.  Plaque-forming ability of relaxin-expressing oncolytic adenovirus. Hep3B 
cells were infected with control adenovirus Ad- Δ E1B or relaxin-expressing 
adenovirus Ad- Δ E1B-RLX. After 4 hours of adsorption, plates were overlaid 
with agarose and incubated. Four, 6, 9, 11, 13, and 16 days after infection, cells 
were visualized by staining with crystal violet; the number of plaques formed 
was counted. Data are representative of three independent experiments with each 
point performed in triplicate.  Error bars are 95% confi dence intervals. 
 Fig. 3.  Relaxin and apoptosis. An in vitro terminal deoxynucleotidyltransferase-
mediated deoxyuridine triphosphate nick end labeling assay was used to assess 
apoptosis. U343, U87MG, C33A, Hep3B, and A549 cells were treated with 
phosphate-buffered saline (PBS) or with 1  μ M camptothecin (CPT) or infected 
with control adenovirus Ad- Δ E1B or relaxing-expressing adenovirus Ad- Δ E1B-
RLX at a multiplicity of infection of 0.1 – 5. Forty-eight hours after treatment, 
apoptotic cells were detected by labeling with 3,3 ′ -diaminobenzidine and terminal 
deoxynucleotidyltransferase and treated with anti-digoxignenin antibody conjugate 
to visualize positive cells. Slides were then counterstained with methyl green. 
DNA strand breakage is indicated by  brown staining . A representative fi eld from 
three independent experiments is shown. (Original magnifi cations = ×100 and 
×400).  Scale bars are 50  μ m for ×40 and 100  μ m for ×400. 
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were evaluated, 32.15 % (95% CI = 25.7 to 38.6) of cells were 
apoptotic after treatment with camptothecin, 32.70% (95% CI = 
25.2 to 40.2) of cells were apoptotic after infection with the 
 relaxin-expressing adenovirus Ad- Δ E1B-RLX, but only 24.15% 
(95% CI = 18.1 to 30.2) of cells were apoptotic after infection 
with Ad- Δ E1B, which does not express relaxin. These same pat-
terns were observed in the rest of the cancer cell lines (U87MG, 
C33A, Hep3B, and A549) evaluated. Thus, relaxin expressed 
from adenoviruses was associated with increased levels of apop-
tosis and is consistent with the results of the cytopathic effect and 
plaque development assays. 
 To further confi rm the role of relaxin as an apoptosis inducer, 
we also performed TUNEL and fl ow cytometry analyses with the 
relaxin-expressing, replication-incompetent adenovirus dl-lacZ-
RLX. Two days after adenovirus transduction, the mean percent-
age of TUNEL-positive apoptotic cells increased by 2.7% (95% 
CI = 0% to 5.8%) in untreated cultures, by 16.0% (95% CI = 
5.7% to 31.7%) in dl-lacZ – transduced cultures, and by 48.6% 
(95% CI = 38.1% to 66.4%) in dl-lacZ-RLX – transduced cultures 
( Table 1 ). In fl ow cytometry analyses, the percentage of cells in 
early apoptosis (i.e., cells positive for annexin-V and negative for 
propidium iodide) was also higher when cells were transduced 
with dl-lacZ-RLX than with dl-lacZ ( Table 1 ). In another series 
of experiments, in which A549 or U343 cells were transfected 
with expression plasmids that did (pSP72 Δ E3-RLX) or did not 
(pSP72 Δ E3) express relaxin, instead of with adenoviruses, we 
found that expression of relaxin statistically signifi cantly in-
creased the percentage of cells in the sub-G 1 population, which 
refl ects the population of apoptotic cells (Supplementary  Fig. 2 , 
available at:  http://jncicancerspectrum.oxfordjournals.org/jnci/
content/vol98/issue20 ). These data demonstrate, for the fi rst time 
to our knowledge, that the expression of relaxin by adenoviruses 
could induce apoptosis. 
 Enhanced Antitumor Effect of Relaxin-Expressing 
Oncolytic Adenovirus 
 The relaxin-expressing oncolytic adenovirus Ad- Δ E1B-RLX 
was next examined for its ability to suppress the growth of 
 human xenograft tumors when administered intratumorally. The 
growth of all xenograft tumors treated with relaxin-expressing 
adenovirus Ad- Δ E1B-RLX was substantially delayed compared 
with that of tumors treated with PBS or with Ad- Δ E1B, which 
does not express relaxin ( Fig. 4 , A). For example, by day 32 af-
ter treatment, tumors of C33A tumor-bearing mice treated with 
PBS reached an average tumor volume of 2252 mm 3 (95% CI = 
1980 to 2524 mm 3 ), those treated with Ad- Δ E1B reached 917 
mm 3 (difference = 1335 mm 3 , 95% CI = 725 to 2449 mm 3 ;  P = 
.007), and those treated with Ad- Δ E1B-RLX reached 77 mm 3 
(difference = 2175 mm 3 , 95% CI = 1184 to 3159 mm 3 ;  P <.001). 
In addition, at day 45 after treatment, complete tumor regression 
was observed in 25% of the mice with Ad- Δ E1B – treated tumors 
and in 50% of those with  Ad- Δ E1B-RLX – treated tumors. 
The tumor growth suppression that was observed in the C33A 
 Table 1.  Relaxin and apoptosis 
Treatment
Assay Cell line PBS CPT Ad- Δ E1B or dl-lacZ Ad- Δ E1B-RXL or dl-lacZ-RLX
TUNEL assay U343 10.5 (5.4 to 15.6) 53.5 (47.0 to 60.0) 32.5 (21.5 to 43.5) 69.7 (65.0 to 74.4)
U87MG 2.5 (1.5 to 3.5) 83.0 (57.3 to 100) 16.5 (11.9 to 21.1) 77.0 (61.2 to 92.8)
C33A 5.65 (2.8 to 8.5) 60.1 (37.4 to 82.8) 45.2 (38.5 to 51.9) 79.8 (61.8 to 97.8)
Hep3B 1.65 (1.1 to 2.2) 71.2 (57.4 to 85.0) 38.5 (36.2 to 40.8) 69.7 (56.0 to 83.4)
A549 3.5 (2.8 to 4.2) 37.5 (32.8 to 42.2) 34.8 (24.9 to 44.7) 75.2 (74.1 to 76.3)
FACS analysis † U343 1.15 (0.8 to 1.5) 32.15 (25.7 to 38.6) 24.15 (18.1 to 30.2) 32.70 (25.2 to 40.2)
U87MG 2.54 (1.5 to 3.6) 70.35 (63.3 to 77.4) 7.04 (6.4 to 7.7) 18.28 (14.6 to 22.0)
C33A 2.93 (2.1 to 3.8) 57.10 (52.0 to 62.2) 21.99 (19.4 to 24.6) 33.03 (28.5 to 37.6)
Hep3B 4.97 (4.2 to 5.7) 13.00 (11.6 to 14.4) 16.58 (12.4 to 20.8) 37.87 (28.4 to 47.3)
A549 0.53 (0.2 to 0.8) 4.48 (2.9 to 6.1) 2.05 (1.7 to 2.4) 13.12 (9.2 to 17.0)
TUNEL assay ‡ U343 1.5 (0 to 4.2) 74.7 (63.8 to 85.5) 15.1 (8.6 to 21.6) 46.3 (44.1 to 48.6)
U87MG 1.9 (0.6 to 3.3) 40.0 (28.5 to 51.5) 15.0 (12.9 to 17.1) 44.4 (38.1 to 50.8)
C33A 3.6 (1.5 to 5.8) 70.5 (56.6 to 84.5) 18.6 (9.8 to 27.3) 54.7 (43.1 to 66.4)
Hep3B 3.3 (2.0 to 4.7) 75.9 (73.1 to 78.6) 23.6 (15.5 to 31.7) 45.3 (38.8 to 51.7)
A549 3.0 (1.1 to 4.9) 69.8 (62.5 to 77.1) 7.8 (5.7 to 10.0) 52.1 (40.1 to 64.1)
FACS analysis § U343 4.11 (2.5 to 5.7) 19.41 (13.4 to 25.4) 3.93 (1.6 to 6.3) 12.84 (10.3 to 15.4)
U87MG 3.61 (1.8 to 5.4) 9.34 (6.5 to 12.2) 4.84 (2.9 to 6.8) 8.33 (7.1 to 9.6)
C33A 4.47 (2.8 to 6.1) 22.50 (14.6 to 30.4) 12.50 (8.8 to 16.2) 16.57 (12.1 to 21.0)
Hep3B 11.76 (9.4 to 14.1) 23.54 (17.4 to 29.7) 5.74 (4.7 to 6.8) 13.41 (10.2 to 16.6)
 A549 5.01 (3.3 to 6.7) 14.76 (13.1 to 16.4) 5.03 (2.5 to 7.6) 11.47 (9.5 to 13.4)
 * TUNEL analysis for apoptotic cells. Cells were infected with Ad-ΔE1B or Ad-ΔE1B-RLX adenoviruses or treated with CPT or PBS and then subjected to TUNEL 
analysis. The number of apoptotic cells per 2000 cells in each micrograph in Fig. 3 was counted. Data are the mean percentage of brown-stained TUNEL-positive 
apoptotic cells (95% confi dence interval [CI]) in triplicate samples. CPT = camptothecin; PBS = phosphate-buffered saline; TUNEL = terminal deoxynucleotidyl-
transferase-mediated dUTP nick end labeling. 
 † Analysis of annexin-V and propidium iodide fl uorescence by fl ow cytometry (FACS = fl uorescence-activated cell sorter). Cells were infected with Ad-ΔE1B or 
Ad-ΔE1B-RLX adenoviruses or treated with CPT or PBS. Cell pellets were resuspended in 100 μL of binding buffer and then reacted with annexin-V (3 μL) and 
propidium iodide (2 μL) at room temperature. The stained cells were then analyzed with a FACS. Data are the percentage of annexin-V-positive and propidium iodide-
negative cells (i.e., cells in early apoptosis) (95% CI). Results are representative of three independent experiments with triplicate samples for each condition. 
 ‡ TUNEL analysis of cells transduced with dl-lacZ or dl-lacZ-RLX at a multiplicity of infection of 5–10 or treated with PBS or CPT. Data are the mean percentage of 
apoptotic cells induced by each treatment (95% CI). Results are representative of three independent experiments, with each point being the mean of triplicate samples. 
 § Analysis of annexin-V and propidium iodide fl uorescence of the cells transduced with adenoviruses dl-lacZ or dl-lacZ-RLX or treated with PBS or CPT. Data are 
the mean percentage of annexin-V-positive and propidium iodide-negative cells (i.e., cells in early apoptosis) (95% CI). Results are representative of three independent 
experiments, with each point being the mean of triplicate samples. 
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 xenograft tumor model was also observed in all other xenograft 
(U343, U87MG, Hep3B, and A549) models tested. 
 We also performed survival analyses for PBS-, Ad- Δ E1B – , 
and Ad- Δ E1B-RLX – treated tumor-bearing mice ( Fig. 4 , B). For 
C33A tumor-bearing mice, 80 days after the beginning of the 
treatment, 100% (95% CI of survival probability = 63.1% to 
100%) of the animals treated with Ad- Δ E1B-RLX were still 
 viable, whereas only 50% (95% CI of survival probability = 
15.7% to 84.3%) of Ad- Δ E1B – treated mice were viable. In all 
xenograft models examined, tumor-bearing mice treated with Ad-
 Δ E1B-RLX survived longer than those treated with Ad- Δ E1B. 
 In Vivo TUNEL, Histologic, and Immunohistochemical 
Characterization 
 The antitumor activity of intratumorally administered re-
laxin-expressing oncolytic adenovirus was further investigated 
by histologic examination. Tumors were harvested from mice 
in each treatment group 7 days after the third of three sequential 
(every other day) adenovirus treatments. Most of the tumor 
mass remaining after treatment with the relaxin-expressing ad-
enovirus Ad- Δ E1B-RLX was necrotic as shown by hematoxy-
lin – eosin staining, whereas necrotic lesions were detected only 
 Fig. 4.  Relaxin-expressing adenovirus Ad- Δ E1B-RLX and the growth of 
established tumors and survival of mice. U343, U87MG, C33A, Hep3B, or A549 
tumors that were growing subcutaneously in the abdomen of nude mice were 
injected intratumorally with phosphate-buffered saline (PBS), control adenovirus 
Ad- Δ E1B, or relaxin-expressing adenovirus Ad- Δ E1B-RLX.  A ) Tumor volume 
was monitored regularly after treatment.  Arrows indicate when treatment was 
given (1 × 10 10 viral particles per 50  μ L for C33A and 5 × 10 10 viral particles per 
50  μ L for U343, U87MG, Hep3B, and A549 per treatment). Data are the means 
and 95% confi dence intervals (CIs) (n = 8 animals per group with U343, C33A, 
Hep3B, or A549 tumors and n = 9 for U87MG tumors).  B ) Overall survival rate. 
The percentage of surviving mice was determined by monitoring the death of 
mice over a period of 80 days after treatment. For mice bearing U343 tumors that 
were treated with PBS, survival probability was 0% (95% CI = 0% to 36.9%); 
for mice treated with Ad- Δ E1B, survival was 62.5% (95% CI = 24.5% to 91.5%); 
and for mice treated with Ad- Δ E1B-RLX, survival was 87.5% (95% CI = 47.3% 
to 99.7%). For mice bearing U87MG tumors that were treated with PBS, survival 
probability was 0% (95% CI = 0% to 33.6%); for mice treated with Ad- Δ E1B, 
survival was 44.4% (95% CI = 13.7% to 78.8%); and for mice treated with Ad-
 Δ E1B-RLX, survival was 88.9% (95% CI = 51.8% to 99.7%). For mice bearing 
C33A tumors treated with PBS, survival probability was 0% (95% CI = 0% to 
36.9%); for mice treated with Ad- Δ E1B, survival was 50% (95% CI = 15.7% 
to 84.3%); and for mice treated with Ad- Δ E1B-RLX, survival was 100% (95% 
CI = 63.1% to 100%). For mice bearing Hep3B tumors treated with PBS, survival 
probability was 0% (95% CI = 0% to 36.9%); for mice treated with Ad- Δ E1B, 
survival was 50% (95% CI = 15.7% to 84.3%); and for mice treated with Ad-
 Δ E1B-RLX, survival was 87.5% (95% CI = 47.3% to 99.7%). For mice bearing 
A549 tumors treated with PBS, survival probability was 25% (95% CI = 0.3% to 
52.7%); for mice treated with Ad- Δ E1B, survival was 62.5% (95% CI = 24.5% to 
91.5%); and for mice treated with Ad- Δ E1B-RLX, survival was 100% (95% CI = 
63.1% to 100%). Ad- Δ E1B-RLX – treated mice survived statistically signifi cantly 
longer ( P <.001 for U87MG,  P = .002 for U343,  P <.001 for C33A,  P <.001 for 
Hep3B,  P <.001 for A549) than mice treated with Ad- Δ E1B or PBS. Survival was 
assessed by the Kaplan – Meier method, and the results were compared with a log-
rank test (SPSS software). All statistical tests were two-sided. 
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on June 19, 2014
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
1490 ARTICLES Journal of the National Cancer Institute, Vol. 98, No. 20, October 18, 2006
in the central region of tumors treated with the control adenovi-
rus Ad- Δ E1B ( Fig. 5 , A). Necrotic lesions in the tumors treated 
with Ad- Δ E1B-RLX were found mainly on the periphery of the 
tumor section but not at the center of tumor, where the blood 
supply is low or nonexistent. These observations  indicate that 
necrosis was most likely the result of injected  virus. 
 We also found more adenoviral particles in wider areas of Ad-
 Δ E1B-RLX – treated tumors, most frequently in the peripheral 
tumor area, than in Ad- Δ E1B – treated tumors. Furthermore, the 
level of apoptosis (as determined by the percentage of TUNEL-
positive cells) was higher in Ad- Δ E1B-RLX – treated tumor tissue 
(40.2%, 95% CI = 31.1% to 49.2%;  P = .023) than in PBS- or 
Ad- Δ E1B – treated tumor tissue (0.7%, 95% CI = 0% to 1.5%, 
and 8.1%, 95% CI = 1.6% to 14.7%, respectively). Apoptotic 
cells were also found mainly in the periphery of the tumor, cor-
responding to the area of necrosis and adenovirus particles de-
tected. Thus, relaxin appeared to be able to induce apoptosis in 
vivo as well as in vitro. 
 Relaxin-Expressing Oncolytic Adenovirus and Collagen 
Content in Tumors 
 Sections from xenograft tumors in nude mice treated with 
PBS, Ad- Δ E1B, or Ad- Δ E1B-RLX were stained with Biebrich’s 
scarlet acid fuchsin (Masson’s trichrome stain). Control tumors 
treated with PBS or Ad- Δ E1B had a high content of collagen, but 
tumors treated with relaxin-expressing Ad- Δ E1B-RLX appeared 
to lack collagen, indicating that relaxin expression was associ-
ated with a reduction in the expression of collagen ( Fig. 5 , B). 
Tumors treated with Ad- Δ E1B-RLX were encapsulated with 
connective tissue, with collagen found only in the boundary area 
between tumor and normal tissue. This result closely parallels 
and supports the fi nding of increased viral spread in the tumor 
mass and enhanced antitumor effect of a relaxin-expressing on-
colytic adenovirus. 
 Inhibition of Tumor Metastasis by Relaxin-Expressing 
Oncolytic Adenovirus 
 Because relaxin-induced matrix metalloproteinase expres-
sion has the potential to increase tumor cell metastasis, we eval-
uated the effect of relaxin-expressing oncolytic adenovirus on 
tumor metastasis by use of the B16BL6 spontaneous tumor 
 metastasis model. The volume of B16BL6 lung metastases was 
 statistically signifi cantly reduced from that in PBS-treated mice 
(268 mg) by treatment with Ad- Δ E1B (48 mg; difference = 
220 mg, 95% CI = 56 to 387 mg;  P = .009) or Ad- Δ E1B-RLX 
(10 mg; difference = 258 mg, 95% CI = 94 to 426 mg;  P = .003) 
 Fig. 5.  Analysis of apoptosis and 
extracellular matrix of tumor tissues. 
C33A tumors were treated with phosphate-
buffered saline (PBS), control adenovirus 
Ad- Δ E1B, or relaxin-expressing adenovirus 
Ad- Δ E1B-RLX, sectioned, and processed 
as indicated.  A ) Tumor sections were 
stained with hematoxylin – eosin (H&E) 
after treatment with PBS, Ad- Δ E1B, or Ad-
 Δ E1B-RLX. Necrotic cells in the periphery 
of the tumor treated with Ad- Δ E1B-RLX are 
indicated by  arrows . Immunohistochemical 
(IHC) staining against adenoviral hexon 
protein was used to localize adenovirus 
in tumor tissue ( brown ). Terminal 
deoxynucleotidyltransferase-mediated 
deoxyuridine triphosphate nick end 
labeling (TUNEL) staining was used to 
identify apoptotic cells in tumor tissue, and 
then tissue was counterstained with methyl 
green.  Arrows indicate apoptotic cells.  B ) 
Masson’s trichrome staining of extracellular 
matrix ( blue ) in the tumor tissue sections. 
Tumors treated with Ad- Δ E1B-RLX were 
smaller than those treated with PBS or Ad-
 Δ E1B.  Arrows indicate extensive bundles of 
collagen ( blue ). (Original magnifi cation = 
×40 and ×400, as indicated)  Scale bars are 
400  μ m for ×40 and 40  μ m for ×400. 
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( Fig. 6 , A). The average relative tumor burden in the lung from 
mice treated with Ad- Δ E1B was reduced by 82% and that from 
mice treated with Ad- Δ E1B-RLX was reduced 96%. Moreover, 
in three of fi ve mice treated with either Ad- Δ E1B or Ad- Δ E1B-
RLX, the formation of metastatic lesions was completely inhib-
ited. Thus, in this model system, the intratumoral injection of 
relaxin-expressing oncolytic adenovirus into the primary tumor 
site appeared to reduce, not promote, the formation of metastatic 
lesions in the lung. 
 Therapeutic Effi cacy of Systemic Treatment With 
Relaxin-Expressing Oncolytic Adenovirus 
 To evaluate the effect of systemically delivered relaxin-
 expressing oncolytic adenovirus on tumor growth, we used the 
Hep1 orthotopic hepatoma model. Systemic treatment of mice 
bearing Hep1 tumors with control Ad- Δ E1B (1.8 mg of tumor 
per mouse; difference = 18.4 mg, 95% CI = 0.5 to 36.7 mg;  P = 
.007) or relaxin-expressing Ad- Δ E1B-RLX (0 mg; difference = 
20.2 mg, 95% CI = 3.7 to 36.7 mg;  P = .004) resulted in a marked 
inhibition of tumor growth compared with PBS-treated controls 
(20.2 mg) ( Fig. 6 , B). In fact, only one of four mice in the 
Ad- Δ E1B group had any liver tumor, and none of the six animals 
in the Ad- Δ E1B-RLX – treated group had any visible macro-
scopic tumor lesions. Therefore, systemically delivered relaxin-
expressing Ad- Δ E1B-RLX adenovirus appears to inhibit hepatic 
tumor growth. 
 Relaxin-Expressing Oncolytic Adenovirus and Toxicity 
 In preliminary analyses, we assessed potential side effects of 
relaxin-expressing adenoviruses by monitoring the level of liver 
transaminases in blood and animal body weights. Intravenous in-
jection of 2 × 10 10 adenoviral particles resulted in moderate 
 increase in AST and ALT levels in one of three mice treated with 
dl-lacZ or Ad- Δ ElB and modest increase in T-bilirubin levels in 
one, two, and one of three mice treated with dl-lacZ, dl-lacZ-
RLX, and Ad- Δ ElB-RLX, respectively ( Table 2 ). Moreover, ad-
enoviruses injected intratumorally at the same dose did not 
increase the level of AST, ALT, or T-bilirubin (data not shown). 
Furthermore, no specifi c abnormality in general appearance and 
microscopic examination was observed. These results indicate 
that relaxin-expressing adenoviruses do not cause evident toxic-
ity. Low-level periportal – sinusoidal lymphocytic accumulation 
was observed histologically in the livers of mice treated systemi-
cally with any one of the four adenoviruses tested ( Fig. 6 , C). No 
substantial weight loss was observed in any mice in response to 
any adenovirus challenge. Thus, neither relaxin-expressing ade-
noviruses, dl-lacZ-RLX or Ad- Δ ElB-RLX, administered by in-
travenous (i.e., systemic) or intratumoral injection caused evident 
 Fig. 6.  Therapeutic effi cacy of relaxin-expressing adenovirus Ad- Δ E1B-RLX 
on spontaneous pulmonary metastasis and orthotopic hepatoma model.  A ) Ad-
 Δ E1B-RLX and spontaneous lung metastasis. B16BL6 tumor-bearing mice were 
treated with phosphate-buffered saline (PBS), Ad- Δ E1B, or Ad- Δ E1B-RLX three 
times every other day, and then the primary tumors were surgically removed. 
Twenty-fi ve days later, the total weight of pulmonary metastatic lesions from 
each mouse was determined. Each  point represents the tumor burden for one 
mouse (fi ve mice per group), and the mean weight of metastatic lesions for each 
group, compared with that of PBS treatment (268 mg), is shown with a  line (for 
Ad- Δ E1B, 48 mg, 95% confi dence interval [CI] = 0 to 161 mg,  P = .009 versus 
PBS; for Ad- Δ E1B-RLX, 10 mg, 95% CI = 0 to 27.55 mg,  P = .003 versus PBS; 
and for Ad- Δ E1B-RLX versus Ad- Δ E1B,  P = .408).  B ) Ad- Δ E1B-RLX and 
orthotopic hepatic tumor growth by systemic administration. Seven days after 
the implantation of 1 × 10 5 Hep1 human hepatic cancer cells into the liver, mice 
were randomly assigned to treatment with PBS (n = 5 mice), Ad- Δ E1B (n = 4 
mice), or Ad- Δ E1B-RLX (n = 6 mice) three times every other day by tail-vein 
injection. Livers were then isolated 42 days after Hep1-cell implant. Each  point 
represents the tumor burden for one mouse, and the mean weight of tumor lesions 
for each group is shown with a  line .  P = .004 for Ad- Δ E1B-RLX versus PBS.  C ) 
Histologic analysis of liver tissue from mice treated with adenovirus dl-lacZ, dl-
lacZ-RLX, Ad- Δ ElB, or Ad- Δ ElB-RLX intravenously (each with 2 × 10 10 viral 
particles in 100  μ L). Hematoxylin – eosin staining.  Scale bar is100  μ m. 
 Table 2.  Evaluation of toxicologic profi le after intravenous administration of PBS, dl-lacZ, dl-lacZ-RLX, Ad- Δ ElB, or Ad- Δ ElB-RLX * 
 Test (unit) 
 PBS  dl-lacZ  dl-lacZ-RLX  Ad- Δ E1B  Ad- Δ E1B-RLX
m1 m2 m3 m1 m2 m3 m1 m2 m3 m1 m2 m3 m1 m2 m3
AST (U/L) 158 148 NT 71 200 329 37 21 15 517 1 2 71 19 125
ALT (U/L) 1 25 15 88 27 457 55 78 69 25 19 80 139 56 25
T-bilirubin (mg/dL) 0.9 4 NT 1 1.1 5.3 4.3 0.8 4.5 0.3 0.7 1.3 0.5 0.5 4.3
Conclusion of chemistry test  −  −  −  −  − +  −  −  − +  −  −  −  −  
 * Each of the three mice (m1, m2, and m3) weighed 20 – 21 g. PBS = phosphate-buffered saline; AST = aspartate aminotransferase; ALT = alanine aminotransferase; 
NT = not tested;  − = normal; + = abnormal liver function. The microscopic examinations for all organs were normal. The general appearance for all mice tested was 
normal. 
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 To elucidate how relaxin increased the potency of adenovi-
ruses, we fi rst investigated the induction of apoptosis by use of 
TUNEL and FACS analyses. Relaxin-expressing adenoviruses 
induced more tumor cells to become apoptotic than non – relaxin-
expressing control adenoviruses. Relaxin expression mediated by 
other adenoviruses, such as green fl uorescent protein – expressing 
replication-incompetent adenovirus (dl-GFP-RLX) and human 
telomerase reverse transcriptase (TERT) promoter – controlled 
replication-competent adenovirus (Ad-TERT- Δ 19-RLX), also 
increased the number of apoptotic cells (data not shown). Fur-
thermore, plasmid-mediated relaxin expression also increased 
the size of the sub-G 1 population in cultures of U343 and A549 
cells, indicating that relaxin may have a direct role in inducing 
apoptosis (Supplementary  Fig. 2 ). 
 A limitation of this study is that the mechanism by which re-
laxin induces apoptosis is not clearly understood. Relaxin acti-
vates the mitogen-activated protein kinase pathway  ( 18 ) and 
causes the release of nitric oxide  ( 19 ) , both of which could play 
a role. The receptors for relaxin, LGR7 and LGR8, have also 
been identifi ed  ( 20 , 21 ) . LGR7 and LGR8 are heterotrimeric 
G-protein – coupled receptors that mediate the action of relaxin 
through the cyclic adenosine 3 ′ ,5 ′ -monophosphate – dependent 
pathway. The possibility cannot be ruled out that the extracellular 
matrix – degradative and  – remodeling functions of relaxin also 
play a role in the induction of apoptosis by changing the number 
and  availability of receptors, as well as rearranging cytoskeletal 
elements in the cell and thus triggering apoptosis. Alternatively, 
induction of apoptosis by relaxin and/or E1A gene product 
of replicating adenovirus could also accelerate viral spread. 
Apoptotic bodies typically contain organelles and/or nuclear 
DNA fragments, and these bodies can play a role in dispersing 
adenovirus throughout the intercellular spaces when apoptotic 
cells are rapidly phagocytosed by neighboring cells  ( 22 ) . Support 
that induced apoptosis increases viral spread is provided by our 
previous reports  ( 12 , 16 ) that adenoviruses, in which the E1B 
19-kDa gene is deleted, potently enhanced apoptosis, increased 
cytolytic potency, and accelerated plaque development. The 
 relaxin-expressing adenovirus that we used is an E1B 19-kDa and 
E1B 55-kDa double-deleted replicating adenovirus-expressing 
relaxin that thus induces relaxin- and E1A-mediated apoptosis 
and direct viral cytolysis, all of which ultimately appeared to 
lead to an increased antitumor effect. 
 Relaxin has been shown to induce the expression of matrix me-
talloproteinases, which may increase the metastatic potential. To 
investigate the effect of relaxin expression on metastases, we used 
the B16BL6 mouse melanoma model. Intratumoral administration 
of Ad- Δ E1B-RLX inhibited the formation of pulmonary metastases 
of B16BL6 melanoma cells in mice. We cannot rule out the possi-
bility that the observed reduction in metastatic potential was also a 
result of a direct inhibitory effect of the relaxin-expressing onco-
lytic adenovirus on the growth of the primary tumor rather than on 
the metastatic potential. The effect of relaxin on metastasis should 
be further and rigorously investigated with other metastatic models. 
Furthermore, systemic delivery of relaxin-expressing oncolytic ad-
enovirus also completely inhibited the growth of orthotopically im-
planted Hep1 hepatocellular carcinomas. Thus, relaxin-expressing 
oncolytic adenovirus appeared to elicit a potent antitumor effect 
against solid tumors and metastatic tumors when injected locally or 
systemically. Moreover, we would expect the therapeutic advantage 
of treatment with relaxin-expressing oncolytic adenovirus that we 
demonstrated in a murine model of spontaneous metastasis to be 
toxicity, compared with their corresponding control adenovi-
ruses, dl-lacZ and Ad- Δ ElB. 
 D ISCUSSION 
 The pressing challenge for contemporary gene therapy is to 
deliver an effective level of therapeutic genes to cancer cells 
throughout a tumor in vivo. The extracellular matrix provides one 
barrier to adenoviral dispersion in a tumor. To overcome this bar-
rier, we inserted the gene for relaxin, an enzyme that degrades the 
extracellular matrix, into adenoviruses. By using these  relaxin-
expressing adenoviruses, we have demonstrated that  relaxin ex-
pression increased the dispersion of the virus from cell to cell 
within the tumor and the induction of tumor cell apoptosis. Thus, 
the expression of relaxin by replicating adenoviruses increased 
the antitumor activity of these adenoviruses in all fi ve tumor xe-
nograft models examined, including the inhibition of tumor 
growth and metastases. This study is, to our knowledge, the fi rst 
to report that the use of relaxin achieved a therapeutic benefi t with 
increased distribution of viral vectors in tumor  tissues. We have 
also demonstrated the ability of relaxin expression by replication-
incompetent adenoviruses to increase transduction effi ciency and 
by oncolytic adenoviruses to increase the survival of mice. 
 An important issue in replicating virus-based cancer gene 
therapy that has received little attention is the limited distribution 
that such viruses have been able to achieve in solid tumors  ( 17 ) . 
To infect cells that are located far from the site of viral inocula-
tion, replication-competent adenovirus must transverse the extra-
cellular space and connective tissue between many cells to reach 
such uninfected cells. To increase the distribution of replicating 
virus within tumors, we explored the use of relaxin, an enzyme 
that degrades the cell matrix, to increase viral spread and tumor 
tissue penetration. We found that relaxin-expressing adenovi-
ruses (dl-lacZ-RLX) penetrated into the core of spheroids com-
posed of tumor cells but that adenoviruses that did not express 
relaxin (dl-lacZ) were restricted to a few outer layers of cells. 
This same effect was observed in xenograft tumors in mice. 
Moreover, the enhanced effi ciency of gene transfer and viral 
spread by use of dl-lacZ-RLX and dl-GFP-RLX was also  evident 
in primary human tumors from patients with breast cancer or 
patients with colon cancer (Supplementary  Fig. 1 , B and Supple-
mentary Fig. 3; available at:  http://jncicancerspectrum.oxford
journals.org/jnci/content/vol98/issue20 ). Thus, relaxin expression 
increased viral spread and tumor tissue penetration both in vitro 
and in vivo. 
 The mechanism by which relaxin increases the ability of ade-
noviruses to infect tumors or spheroids appears to be related to its 
degradation of the extracellular matrix. We observed that the 
gene transfer effi ciency of relaxin-expressing adenoviruses was 
greater than that of non – relaxin-expressing adenoviruses. Be-
cause tumor spheroids were cultured with viruses for 3 days, 
residual relaxin-expressing adenoviruses had enough time to in-
fect cells progressively closer to the core of the spheroid. In vivo, 
repeated treatments of established xenografts with adenoviruses 
provided enough time for relaxin to reduce the amount of extra-
cellular matrix in tumor tissue to allow the penetration and spread 
of adenoviruses into the tumor. In both tumors and spheroids, 
previous exposure to relaxin-expressing replication-incompetent 
dl-lacZ-RLX adenoviruses appeared to make the tumor environ-
ment more favorable to subsequent viral infections. 
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on June 19, 2014
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
Journal of the National Cancer Institute, Vol. 98, No. 20, October 18, 2006 ARTICLES 1493
enhanced in humans because human tumor cells are more permis-
sive to adenoviral infection and replication than murine cells. 
 The pressing challenge for contemporary gene therapy is to 
deliver enough therapeutic genes to enough cancer cells in vivo. 
The use of relaxin expression from replicating adenoviruses 
 increased the ability of adenovirus to disperse from one cell to 
another cell and increased the induction of apoptosis in all fi ve 
tumor xenograft models examined. Thus, the expression of re-
laxin may increase the effi cacy of virus-mediated cancer gene 
therapy. 
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